<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577926</url>
  </required_header>
  <id_info>
    <org_study_id>12-181</org_study_id>
    <nct_id>NCT02577926</nct_id>
  </id_info>
  <brief_title>The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia</brief_title>
  <acronym>Ruxo-BEAT</acronym>
  <official_title>Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of&#xD;
      clonal hematological malignancies that are characterized by chronic myeloproliferation,&#xD;
      splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms&#xD;
      including pruritus, night sweats, fever, weight loss, cachexia, and diarrhea. In addition,&#xD;
      due to elevated numbers of leucocytes, erythrocytes and/or platelets, the disease course can&#xD;
      be complicated by thromboembolic disease, hemorrhage, and leukemic transformation as well as&#xD;
      myelofibrosis.&#xD;
&#xD;
      Patients with polycythemia vera (PV) typically harbor an increased number of blood cells from&#xD;
      all three hematopoietic cell lineages due to clonal amplification of hematopoetic stem cells,&#xD;
      while patients with essential thrombocythemia (ET) typically show a predominant expansion of&#xD;
      the megakaryocytic lineage. Most patients with PV below the age of 60 years are currently&#xD;
      being treated with acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET&#xD;
      have an almost normal life expectancy and often do not require specific treatment. However,&#xD;
      PV- as well as ET-patients with a higher risk for complications require cytoreductive&#xD;
      treatment. In addition, constitutional symptoms can be unbearable to patients even in the&#xD;
      absence of bona fide high risk factors, and these patients may similarly benefit from&#xD;
      antineoplastic therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycythemia vera (PV) and essential thrombocythemia (ET) are classical Philadelphia-negative&#xD;
      myeloproliferative neoplasms (MPN) that are characterized by an excess of cells in the&#xD;
      peripheral blood, clonal bone marrow hyperplasia, and extramedullary hematopoiesis. The&#xD;
      symptoms of these patients may range from asymptomatic disease to symptomatic disease that&#xD;
      may significantly affect their activities of daily living, such as severe generalized&#xD;
      pruritus, night sweats and fevers, erythromelalgia, bone and muscle pain, weight loss, and&#xD;
      fatigue. Moreover, the patients may develop thromboembolic and hemorrhagic complications,&#xD;
      transition to myelofibrosis (MF), and transformation to acute leukemia. In principle, the&#xD;
      only potentially curative therapy for MPNs is allogenic stem cell transplantation (allo-SCT).&#xD;
      However, due to significant transplant-associated morbidity and mortality, this therapeutic&#xD;
      option is only applied in exceptional cases of ET or PV. The majority of patients do not&#xD;
      qualify for allo-SCT since the risks of this treatment clearly outweigh the potential&#xD;
      benefits. Moreover, even with a non-transplantation approach, patients with ET and PV have a&#xD;
      life expectancy comparable to or close to healthy age-matched control persons. For patients&#xD;
      with standard risk PV, phlebotomy and acetylsalicylic acid are standard of care (target&#xD;
      hematocrit below 45 %), while patients with standard risk ET should receive either no&#xD;
      specific treatment or acetylsalicylic acid (provided that no microvascular symptoms or&#xD;
      secondary acquired von Willebrand syndrome are present).&#xD;
&#xD;
      However, in patients who are at high risk to develop thromboembolic or hemorrhagic&#xD;
      complications (high-risk patients), cytoreductive treatment is generally indicated to prevent&#xD;
      these potentially life-threatening complications. In PV and ET, high risk patients are&#xD;
      characterized by advanced age (&gt; 60 years) and / or a history of thromboembolic or&#xD;
      hemorrhagic events {1,2,3}. In ET, a platelet count &gt; 1500 x 109/l is associated with an&#xD;
      increased risk of bleeding, and thus should result in a platelet lowering treatment {2}. In&#xD;
      PV, in addition to the risk-score based therapy, cytoreduction is also required in patients&#xD;
      with progressive or marked myeloproliferation (leukocytosis, thrombocytosis, symptomatic&#xD;
      splenomegaly, increase of frequency of phlebotomy requirement), or devastating constitutional&#xD;
      symptoms {1,2,4}. In Germany, best available therapy (BAT) includes approved drugs such as&#xD;
      hydroxyurea (HU; approved for both PV and ET) and anagrelide (approved for second-line&#xD;
      treatment of ET) and non-approved options such as alpha-interferon, pipobroman, busulfan (in&#xD;
      elderly patients), and radioactive phosphorus (32P). In rare cases, patients may also benefit&#xD;
      from splenic irradiation or splenectomy.&#xD;
&#xD;
      Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for&#xD;
      the treatment of symptomatic myelofibrosis. The compound was shown to be superior to&#xD;
      hydroxyurea in reducing splenomegaly and constitutional symptoms. Ruxolitinib is currently&#xD;
      studied in phase 2 and phase 3 clinical trials for HU-resistant or HU-intolerant PV and ET.&#xD;
      The aim of the present study is to assess the feasibility, efficacy, and safety of&#xD;
      ruxolitinib treatment vs. BAT in patients with high-risk PV or -ET.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al Blood 2009</measure>
    <time_frame>at month 6</time_frame>
    <description>The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al Blood 2009</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>at month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The complete response rate (CR) at month 6 as defined by Barosi et al Blood 2013 (revised ELN response criteria)</measure>
    <time_frame>month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of complete responses (CHR) at month 12 as defined by Barosi et al Blood 2009</measure>
    <time_frame>month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy as assessed by the absence of phlebotomy (Hct &lt;45%)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy as assessed by the reduction in spleen size (palpable spleen that is reduced by &gt; 50% from baseline measured by palpation and ultrasound) OR platelet count &lt; 600 x 10^9/l (ET)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving both durable absence of phlebotomy eligibility AND durable spleen volume reduction measured by palpation and ultrasound (PV) OR durable platelet count &lt;600 x 10^9/l (ET) (durable defined as &gt;3 months) {Barosi et al 2013)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of overall clinicohematologic remissions (CR + PR) according to both guidelines (Barosi et al 2009 and 2013)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Polycythemia Vera (PV)</condition>
  <condition>Essential Thrombocythemia (ET)</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best available therapy (BAT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <other_name>Study drug</other_name>
    <other_name>Jakavi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAT</intervention_name>
    <description>BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).</description>
    <arm_group_label>Best available therapy (BAT)</arm_group_label>
    <other_name>Control Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. written informed consent and willing to comply with treatment and to follow up&#xD;
             assessments and procedures&#xD;
&#xD;
          2. &gt;18 years old&#xD;
&#xD;
          3. Patient´s ECOG performance status: 0-2&#xD;
&#xD;
          4. Patient must fulfill WHO 2008 diagnostic criteria for either PV or ET. PV- and&#xD;
             ET-patients have to be classified as high risk according to defined criteria.&#xD;
&#xD;
             For patients with high risk PV OR PV with indication for cytoreductive therapy due to&#xD;
             progressive myeloproliferation, AT LEAST ONE of the following must be fulfilled:&#xD;
&#xD;
               -  Age &gt;60 years&#xD;
&#xD;
               -  Previous documented thrombosis or thromboembolism&#xD;
&#xD;
               -  Platelet count &gt; 1500 x 10^9/L&#xD;
&#xD;
               -  Poor tolerance of phlebotomy or frequent phlebotomy requirement&#xD;
&#xD;
               -  Symptomatic or progressive splenomegaly&#xD;
&#xD;
               -  Severe disease-related symptoms&#xD;
&#xD;
               -  Progressive leukocytosis with leukocyte count &gt; 20 x 10^9/L&#xD;
&#xD;
             For patients with high risk ET, AT LEAST ONE of the following must be fulfilled:&#xD;
&#xD;
               -  Age &gt; 60 years&#xD;
&#xD;
               -  Platelet count&gt; 1500 x 10^9/L&#xD;
&#xD;
               -  Previous thrombosis or thromboembolism&#xD;
&#xD;
               -  Previous severe hemorrhage related to ET.&#xD;
&#xD;
          5. Patients must fulfill the following criteria regarding prior therapy:&#xD;
&#xD;
        PV patients: Never treated with cytoreductive drugs except short- term therapy (up to 6&#xD;
        weeks maximum) with ONE of the following drugs: hydroxyurea, anagrelide, or interferon&#xD;
        (phlebotomy and/or aspirin are allowed) ET patients: Naïve and pretreated patients may be&#xD;
        entered in this trial 7. adequate liver function, AST, and ALT ≤ 2 the institutional ULN&#xD;
        value, unless directly attributable to the patient's MPN 8. creatinine clearance &gt;40ml/min&#xD;
        calculated according to the modified formula of Cockcroft and Gault, eGFR, or directly&#xD;
        measured after 24h-urine collection 9. ability to swallow and retain oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. criteria for post PV-MF or post ET-MF are met&#xD;
&#xD;
          2. previous ruxolitinib treatment&#xD;
&#xD;
          3. history of anaphylaxis following exposure to the BAT drug of choice&#xD;
&#xD;
          4. inadequate bone marrow reserve as demonstrated by ANC ≤ 1 x 10^9/l OR platelet count&#xD;
             &lt;50 x 10^9/l&#xD;
&#xD;
          5. known hepatitis B or C or HIV infection&#xD;
&#xD;
          6. other severe, concurrent diseases, including tuberculosis, serious cardiac functional&#xD;
             dysfunction (class III or IV), uncontrolled diabetes, uncontrolled hypertension,&#xD;
             severe pulmonary disease, or major organ malfunction&#xD;
&#xD;
          7. history of active substance or alcohol abuse within the last year&#xD;
&#xD;
          8. Female patients who are pregnant or nursing&#xD;
&#xD;
          9. participation in another interventional trial and/or used investigational agents or&#xD;
             concurrent anticancer treatment for concomitant disease within the last 4 weeks of&#xD;
             registration&#xD;
&#xD;
         10. Any circumstances at the time the study entry that would preclude completion of the&#xD;
             study or the required follow-up prohibits inclusion into this study&#xD;
&#xD;
         11. active malignancy during the previous 3 years except for treated cervical&#xD;
             intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell&#xD;
             carcinoma of the skin, each with no evidence for recurrence in the past 3 years&#xD;
&#xD;
         12. active bacterial, viral, or fungal infection&#xD;
&#xD;
         13. medical condition requiring prolonged use of oral corticosteroids with a dose of more&#xD;
             than 20 mg per day (&gt; 1 month)&#xD;
&#xD;
         14. severe cerebral dysfunction and/or legal incapacity&#xD;
&#xD;
         15. history of active splanchnic vein thrombosis within the last 3 months (includes&#xD;
             Budd-Chiari, portal vein, splenic and mesenteric thrombosis)&#xD;
&#xD;
         16. thyroid dysfunction which is not adequately controlled&#xD;
&#xD;
         17. Fertile men or women of childbearing potential cannot be included unless they are:&#xD;
             surgically sterile or &gt;2 years after the onset of menopause and/or willing to use a&#xD;
             highly effective contraceptive method (Pearl Index &lt;1)&#xD;
&#xD;
         18. patients who are taking any of the following prohibited medication: clarithromycin,&#xD;
             telithromycin, troleandomycin, ritonavir, indinavir, saquinavir, nelfinavir,&#xD;
             amprenavir, lopinavir -itraconazole, ketoconazole, voriconazole, fluconazole&#xD;
&#xD;
         19. Patients who suffer from galactose intolerance, lack of lactose or a&#xD;
             glucose-galactose-malabsortion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Koschmieder, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH University Hospital MK4</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rems-Murr Klinikum Winnenden</name>
      <address>
        <city>Winnenden</city>
        <state>Baden-Württemberg</state>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III. Medizinischen Klinik des Klinikums rechts der Isar der TU München</name>
      <address>
        <city>Müchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord Medizinische Klinik 5</name>
      <address>
        <city>Nürnberg</city>
        <state>Bayern</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <state>Hessen</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47228</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Minden</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Düsseldorf</city>
        <state>North Rhine Westphalia</state>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachesen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH Klinik für Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg - Klinik für Innere Medizin I</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Jena - Klinik für Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <zip>07705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIVERSITÄTSKLINIKUM Schleswig-Holstein - Klinik für Hämatologie und Onkologie, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

